Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service CSF shunts cases in Ohio: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 10% on average (47 state-years, 2020–2024): read it as a direction with a margin.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 5 | 349 | 47% |
| 2020 | 3 | 265 | 50% |
| 2021 | 3 | 313 | 53% |
Ventriculoperitoneal shunt placement and revision, including normal-pressure hydrocephalus. Professional codes (what the surgeon bills): CPT 62223, 62230.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in Ohio; 4 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Aneurysm & intracranial embolization | 15 | 485+7.7%/yr | +7.7%/yr | 0.41.0× | 0% | 720 in 2030+6.9%/yr |
| Stroke thrombectomy |
CSF shunts in every state, and its device makers · Every procedure market in Ohio · Every state · Compare with Illinois
| 2024 |
| 266 |
| 60% |
| 2025 est. | ≈ 260 | – |
| 2026 est. | ≈ 270 | – |
| 2022 | 5 | 276 | 56% |
| 2023 | 4 | 251 | 58% |
| 2024 | 5 | 266 | 60% |
| 2025 from claims | – | 259 209–304 | 61% |
| 2026 forecast | – | 266 208–334 | 61% |
| 2027 forecast | – | 267 198–353 | 61% |
| 2028 forecast | – | 268 190–370 | 61% |
| 2029 forecast | – | 269 183–385 | 62% |
| 2030 forecast | – | 269 177–400 | 62% |
In 2025, 100% inpatient hospital.
| +4.2%/yr |
| 0.4 |
| 0% |
| 340 in 2030+12%/yr |
| Missouri | 0 | 137−5.5%/yr | −5.5%/yr | 0.2 | 0% | 180 in 2030+4.6%/yr |
| Michigan | 0 | 130−12%/yr | −12%/yr | 0.2 | 0% | 290 in 2030+14%/yr |
| Wisconsin | 0 | 105+1.8%/yr | +1.8%/yr | 0.2 | 0% | 120 in 2030+2.7%/yr |
| 16 |
| 453−0.3%/yr |
| −0.3%/yr |
| 0.41.0× |
| 0% |
| 410 in 2030−1.6%/yr |
| DBS & VNS | 9 | 430−6.8%/yr | −6.8%/yr | 0.41.1× | 0% | 580 in 2030+5.2%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
Johnson & Johnson MedTech leads with 49% of company spending on these surgeons in 2025, −45 pts on 2024.
In 2025, 6 companies reported engagement with Ohio’s surgeons worth $12K in consulting, speaking, meals and travel tied to these products, about $2,449 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 4 clearances and approvals in the category, 1 recalled product line. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.